These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23436338)

  • 1. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
    Berg AK; Mandrekar SJ; Ziegler KL; Carlson EC; Szabo E; Ames MM; Boring D; Limburg PJ; Reid JM;
    J Clin Pharmacol; 2013 Apr; 53(4):403-12. PubMed ID: 23436338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative bioavailability of sulindac in capsule and tablet formulations.
    Reid JM; Mandrekar SJ; Carlson EC; Harmsen WS; Green EM; McGovern RM; Szabo E; Ames MM; Boring D; Limburg PJ;
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):674-9. PubMed ID: 18349286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption of sulindac from a novel (Pro-SorbTM) liquid formulation.
    Kanfer I; Brown C; Konings M; Swarbrick J
    Biopharm Drug Dispos; 1996 Apr; 17(3):209-21. PubMed ID: 8983396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral dosing paradigms (gavage versus diet) on pharmacokinetics and pharmacodynamics.
    Kapetanovic IM; Krishnaraj R; Martin-Jimenez T; Yuan L; van Breemen RB; Lyubimov A
    Chem Biol Interact; 2006 Dec; 164(1-2):68-75. PubMed ID: 17027946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.
    Tang YJ; Hu K; Huang WH; Wang CZ; Liu Z; Chen Y; Ouyang DS; Tan ZR; Zhou HH; Yuan CS
    Biomed Res Int; 2017; 2017():4189678. PubMed ID: 28331852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase II trial of sulindac for lung cancer chemoprevention.
    Limburg PJ; Mandrekar SJ; Aubry MC; Ziegler KL; Zhang J; Yi JE; Henry M; Tazelaar HD; Lam S; McWilliams A; Midthun DE; Edell ES; Rickman OB; Mazzone P; Tockman M; Beamis JF; Lamb C; Simoff M; Loprinzi C; Szabo E; Jett J;
    Lung Cancer; 2013 Mar; 79(3):254-61. PubMed ID: 23261228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
    Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
    Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
    Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.
    van Stolk R; Stoner G; Hayton WL; Chan K; DeYoung B; Kresty L; Kemmenoe BH; Elson P; Rybicki L; Church J; Provencher K; McLain D; Hawk E; Fryer B; Kelloff G; Ganapathi R; Budd GT
    Clin Cancer Res; 2000 Jan; 6(1):78-89. PubMed ID: 10656435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors.
    Witta SE; Gustafson DL; Pierson AS; Menter A; Holden SN; Basche M; Persky M; O'Bryant CL; Zeng C; Baron A; Long ME; Gibbs A; Kelly K; Bunn PA; Chan DC; Pallansch P; Eckhardt SG
    Clin Cancer Res; 2004 Nov; 10(21):7229-37. PubMed ID: 15534096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
    Wong CC; Cheng KW; Papayannis I; Mattheolabakis G; Huang L; Xie G; Ouyang N; Rigas B
    Pharm Res; 2015 May; 32(5):1663-75. PubMed ID: 25392229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of NAG-1/GDF15 in the inhibition of intestinal polyps in APC/Min mice by sulindac.
    Wang X; Kingsley PJ; Marnett LJ; Eling TE
    Cancer Prev Res (Phila); 2011 Jan; 4(1):150-60. PubMed ID: 21205743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor.
    Sung JW; Yun HY; Park S; Kim YJ; Yee J; Lee KE; Song B; Chung JE; Gwak HS
    Pharm Res; 2020 Jan; 37(3):44. PubMed ID: 31993760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease].
    Mignot A; Lefebvre MA; Couet W; Dourthe C; Marechaud R; Fourtillan JB
    Therapie; 1989; 44(4):253-6. PubMed ID: 2595642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.
    O'Connor R; O'Leary M; Ballot J; Collins CD; Kinsella P; Mager DE; Arnold RD; O'Driscoll L; Larkin A; Kennedy S; Fennelly D; Clynes M; Crown J
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):79-87. PubMed ID: 16642371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers.
    Palma-Aguirre JA; Lopez-Gamboa M; Cariño L; Burke-Fraga V; González-de la Parra M
    Clin Ther; 2010 Feb; 32(2):357-64. PubMed ID: 20206793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
    Thompson PA; Hsu CH; Green S; Stopeck AT; Johnson K; Alberts DS; Chow HH
    Cancer Prev Res (Phila); 2010 Jan; 3(1):101-7. PubMed ID: 20051377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines.
    Lim JT; Piazza GA; Han EK; Delohery TM; Li H; Finn TS; Buttyan R; Yamamoto H; Sperl GJ; Brendel K; Gross PH; Pamukcu R; Weinstein IB
    Biochem Pharmacol; 1999 Oct; 58(7):1097-107. PubMed ID: 10484067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.